dry eye syndromes
Showing NaN - NaN of 8
Dry Eye Syndromes Trial in Sacramento, Houston (Oculeve Intranasal Lacrimal Neurostimulator)
Completed
- Dry Eye Syndromes
- Oculeve Intranasal Lacrimal Neurostimulator
-
Sacramento, California
- +1 more
Sep 22, 2021
Dry Eye Syndromes Trial in Houston (Intranasal Tear Neurostimulator (ITN) [TrueTear®])
Terminated
- Dry Eye Syndromes
- Intranasal Tear Neurostimulator (ITN) [TrueTear®]
-
Houston, TexasBaylor College of Medicine - Department of Ophthalmology
Jul 23, 2021
Dry Eye Syndromes, Keratoconjunctivitis Sicca Trial in United States (KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121
Completed
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- KPI-121 0.25% Ophthalmic Suspension
- Vehicle of KPI-121 0.25% Ophthalmic Suspension
-
Phoenix, Arizona
- +59 more
Jan 19, 2021
Dry Eye Syndromes, Keratoconjunctivitis Sicca Trial in United States (KPI-121, Placebo)
Completed
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- KPI-121
- Placebo
-
Artesia, California
- +10 more
Jan 4, 2021
Dry Eye Syndromes, Keratoconjunctivitis Sicca Trial in United States (KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121
Completed
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- KPI-121 0.25% Ophthalmic Suspension
- Vehicle of KPI-121 0.25% Ophthalmic Suspension
-
Birmingham, Alabama
- +61 more
Dec 10, 2020
Dry Eye Syndromes Trial in United States (SJP-0035 0.001%, Placebo)
Completed
- Dry Eye Syndromes
- SJP-0035 0.001%
- Placebo
-
Chandler, Arizona
- +22 more
Apr 13, 2019
Dry Eye Syndromes Trial in United States (AGN-223575 ophthalmic solution, AGN-223575 vehicle ophthalmic solution)
Completed
- Dry Eye Syndromes
- AGN-223575 ophthalmic solution
- AGN-223575 vehicle ophthalmic solution
-
Phoenix, Arizona
- +27 more
Mar 15, 2019